Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

OPKO Health, Inc. (OPK)

1.47   0.01 (0.68%) 12-02 16:00
Open: 1.42 Pre. Close: 1.46
High: 1.48 Low: 1.39
Volume: 2,254,368 Market Cap: 1,136(M)

Technical analysis

as of: 2022-12-02 4:25:07 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 2.01     One year: 2.27
Support: Support1: 1.36    Support2: 1.13
Resistance: Resistance1: 1.72    Resistance2: 1.95
Pivot: 1.55
Moving Average: MA(5): 1.44     MA(20): 1.59
MA(100): 2.05     MA(250): 2.8
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 27.5     %D(3): 21.8
RSI: RSI(14): 38.6
52-week: High: 5.25  Low: 1.36
Average Vol(K): 3-Month: 2,301 (K)  10-Days: 3,061 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ OPK ] has closed above bottom band by 30.8%. Bollinger Bands are 10.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.48 - 1.49 1.49 - 1.49
Low: 1.37 - 1.38 1.38 - 1.39
Close: 1.46 - 1.47 1.47 - 1.48

Company Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Headline News

Thu, 01 Dec 2022
Talkspace CEO on Plans to Grow B2B, 'Significantly Decrease the Cash Burn' - Behavioral Health Business

Tue, 29 Nov 2022
Here's Why You Should Hold OPKO Health (OPK) Stock For Now - Zacks Investment Research

Tue, 22 Nov 2022
Finance Stocks Lead Highs Tuesday; Markets Rise - InvestorsObserver

Tue, 08 Nov 2022
OPKO Health down 5% following Q3 top and bottom line misses (NASDAQ:OPK) - Seeking Alpha

Tue, 08 Nov 2022
Opko Health (OPK) Q3 2022 Earnings Call Transcript - The Motley Fool

Mon, 31 Oct 2022
Insiders of OPKO Health, Inc. (NASDAQ:OPK) were rewarded after last week’s 5.1% gain - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 773 (M)
Shares Float 401 (M)
% Held by Insiders 46 (%)
% Held by Institutions 24.6 (%)
Shares Short 37,450 (K)
Shares Short P.Month 37,360 (K)

Stock Financials

EPS -0.18
EPS Est Next Qtl -0.06
EPS Est This Year -0.19
EPS Est Next Year -0.08
Book Value (p.s.) 2.1
Profit Margin (%) -26
Operating Margin (%) -20.1
Return on Assets (ttm) -6.6
Return on Equity (ttm) -18.7
Qtrly Rev. Growth -53.5
Gross Profit (p.s.) 0.65
Sales Per Share 1.57
EBITDA (p.s.) -0.19
Qtrly Earnings Growth 0
Operating Cash Flow -69 (M)
Levered Free Cash Flow 14 (M)

Stock Valuations

PE Ratio -8.22
PEG Ratio -0.3
Price to Book value 0.69
Price to Sales 0.93
Price to Cash Flow -16.42

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.